Edward Tenthoff
Stock Analyst at Piper Sandler
(3.44)
# 1,518
Out of 4,622 analysts
183
Total ratings
42.47%
Success rate
5.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Reiterates: Overweight | $11 | $3.79 | +190.24% | 6 | Oct 11, 2024 | |
| KRON Kronos Bio | Reiterates: Overweight | $6 | $0.92 | +551.47% | 6 | Oct 8, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $62 | $18.44 | +236.23% | 10 | Oct 8, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Overweight | $53 | $33.67 | +57.41% | 5 | Sep 23, 2024 | |
| SKYE Skye Bioscience | Reiterates: Overweight | $20 | $4.29 | +366.20% | 3 | Sep 20, 2024 | |
| OPK OPKO Health | Reiterates: Overweight | $3 | $1.46 | +105.48% | 6 | Sep 17, 2024 | |
| MRNA Moderna | Maintains: Overweight | $157 → $115 | $58.29 | +97.29% | 11 | Sep 13, 2024 | |
| SYRS Syros Pharmaceuticals | Reiterates: Overweight | $13 → $5 | $1.93 | +159.07% | 6 | Aug 13, 2024 | |
| CUE Cue Biopharma | Maintains: Overweight | $8 → $3 | $1.23 | +143.90% | 4 | Jul 26, 2024 | |
| MESO Mesoblast | Upgrades: Overweight | $4 → $11 | $10.08 | +9.13% | 3 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.93 | +224.54% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.03 | +680.49% | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $46.85 | +124.12% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $50.00 | +80.00% | 3 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $12 | $1.55 | +674.19% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $3.09 | +94.17% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 | $0.37 | +1,266.12% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 → $9 | $0.96 | +837.50% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.45 | +244.83% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $37 → $24 | $21.29 | +12.73% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $3.48 | +331.03% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $45.02 | +24.39% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $217 | $284.32 | -23.68% | 12 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.51 | +298.41% | 3 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $55 | $26.13 | +110.49% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $7 | $0.05 | +13,652.46% | 2 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $1.82 | +1,603.30% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3 | $0.51 | +486.28% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $1.42 | +322.54% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $0.81 | +1,015.66% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $19.60 | +124.49% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $26.46 | +39.83% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3,036 → $880 | $0.15 | +604,711.00% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $536.70 | -34.04% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.40 | +9,542.86% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $481.71 | -32.95% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $26.23 | +37.25% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $2.71 | +822.51% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $3.18 | +4,616.98% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $15.00 | +253.33% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $1.34 | +102,885.07% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $1,015.67 | - | 11 | Feb 13, 2017 |
Sutro Biopharma
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $3.79
Upside: +190.24%
Kronos Bio
Oct 8, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.92
Upside: +551.47%
Arrowhead Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $62
Current: $18.44
Upside: +236.23%
Dyne Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $53
Current: $33.67
Upside: +57.41%
Skye Bioscience
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.29
Upside: +366.20%
OPKO Health
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.46
Upside: +105.48%
Moderna
Sep 13, 2024
Maintains: Overweight
Price Target: $157 → $115
Current: $58.29
Upside: +97.29%
Syros Pharmaceuticals
Aug 13, 2024
Reiterates: Overweight
Price Target: $13 → $5
Current: $1.93
Upside: +159.07%
Cue Biopharma
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $1.23
Upside: +143.90%
Mesoblast
Jul 23, 2024
Upgrades: Overweight
Price Target: $4 → $11
Current: $10.08
Upside: +9.13%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.93
Upside: +224.54%
Jun 21, 2024
Reiterates: Overweight
Price Target: $8
Current: $1.03
Upside: +680.49%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $46.85
Upside: +124.12%
Jun 17, 2024
Reiterates: Overweight
Price Target: $90
Current: $50.00
Upside: +80.00%
Jun 17, 2024
Maintains: Overweight
Price Target: $9 → $12
Current: $1.55
Upside: +674.19%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $3.09
Upside: +94.17%
Apr 3, 2024
Maintains: Overweight
Price Target: $5
Current: $0.37
Upside: +1,266.12%
Apr 3, 2024
Reiterates: Overweight
Price Target: $10 → $9
Current: $0.96
Upside: +837.50%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.45
Upside: +244.83%
Feb 28, 2024
Downgrades: Neutral
Price Target: $37 → $24
Current: $21.29
Upside: +12.73%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $3.48
Upside: +331.03%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $45.02
Upside: +24.39%
Dec 14, 2023
Maintains: Overweight
Price Target: $210 → $217
Current: $284.32
Upside: -23.68%
Dec 11, 2023
Maintains: Overweight
Price Target: $8 → $10
Current: $2.51
Upside: +298.41%
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $26.13
Upside: +110.49%
Sep 28, 2023
Maintains: Overweight
Price Target: $6 → $7
Current: $0.05
Upside: +13,652.46%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $1.82
Upside: +1,603.30%
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $0.51
Upside: +486.28%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $1.42
Upside: +322.54%
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.81
Upside: +1,015.66%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $19.60
Upside: +124.49%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $26.46
Upside: +39.83%
May 13, 2022
Maintains: Overweight
Price Target: $3,036 → $880
Current: $0.15
Upside: +604,711.00%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $536.70
Upside: -34.04%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.40
Upside: +9,542.86%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $481.71
Upside: -32.95%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $26.23
Upside: +37.25%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $2.71
Upside: +822.51%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $3.18
Upside: +4,616.98%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $15.00
Upside: +253.33%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $1.34
Upside: +102,885.07%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $1,015.67
Upside: -